Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/6/2025

Albumin Infusion Guidelines

Introduction to Albumin Infusion

  • Albumin infusion should not be used routinely in most clinical scenarios, with the strongest evidence supporting its use only in patients with cirrhosis undergoing large-volume paracentesis or with spontaneous bacterial peritonitis, as recommended by the American Thoracic Society and the American College of Chest Physicians 1

Indications for Albumin Infusion

  • The American College of Chest Physicians and the American Association for the Study of Liver Diseases recommend albumin infusion in patients with cirrhosis undergoing large-volume paracentesis (>5L) or with spontaneous bacterial peritonitis, with specific dosing recommendations:
  • Albumin may be considered as a second-line fluid for resuscitation in septic shock, after crystalloids, although the evidence is limited, as suggested by the 2021 Surviving Sepsis Campaign guidelines 1
  • Patients with serum bilirubin >4 mg/dL and baseline AKI are at highest risk and most likely to benefit from intravenous albumin for spontaneous bacterial peritonitis, as noted by the American Association for the Study of Liver Diseases 2
  • Intravenous albumin is recommended as the volume expander of choice in hospitalized patients with cirrhosis and ascites presenting with AKI, with a recommended dose of 1 g/kg of body weight daily for 2 consecutive days (maximum 100 g/day), according to the American Association for the Study of Liver Diseases 2
  • Albumin should be used in conjunction with vasoactive drugs (terlipressin, norepinephrine, or octreotide/midodrine) for hepatorenal syndrome (HRS-AKI), as recommended by the American Association for the Study of Liver Diseases 2

Contraindications and Precautions

  • The American Thoracic Society recommends against the routine use of albumin for volume replacement in critically ill adults, nutritional supplementation, uncomplicated ascites in cirrhosis, and correction of hypoalbuminemia without specific clinical indications 1
  • The American Association for the Study of Liver Diseases recommends against using albumin in patients with cirrhosis and uncomplicated ascites 2
  • Contraindications for albumin use include fluid overload, hypotension, hemodilution requiring RBC transfusion, anaphylaxis, and peripheral gangrene from dilution of natural anticoagulants, as stated by the International Collaboration for Transfusion Medicine Guidelines 1

Administration and Monitoring

  • Albumin should be administered by intravenous infusion only, with careful monitoring to prevent circulatory overload and other adverse effects, as recommended by the American Association for the Study of Liver Diseases 2, 1
  • The administration rate should not exceed 2 mL per minute to avoid circulatory embarrassment and pulmonary edema in hypoproteinemia, as recommended by the American Association for the Study of Liver Diseases 2
  • Patients should be monitored carefully for signs of circulatory overload, hypotension, allergic reactions, hemodilution requiring RBC transfusion, and anaphylaxis when receiving albumin infusion, as recommended by the American College of Chest Physicians 1
  • The use of intravenous albumin is expensive, with a cost of approximately $130 per 25g in the US, and requires large volumes of plasma for manufacturing, making cost-effectiveness an important consideration when selecting appropriate clinical scenarios for its use, as noted by the International Collaboration for Transfusion Medicine Guidelines and the American Association for the Study of Liver Diseases 2, 1

Ongoing Research and Future Directions

  • Several large randomized clinical trials are currently investigating albumin use in various conditions, including albumin in septic shock, albumin in high-risk cardiac surgery, long-term albumin administration in decompensated cirrhosis, and albumin in acute kidney injury, which may provide additional clarity in the future, as reported by the American College of Chest Physicians and the American Thoracic Society 1
  • Implementation of evidence-based guidelines can reduce inappropriate use and costs of intravenous albumin, according to the American Association for the Study of Liver Diseases and the American College of Chest Physicians 2, 1